posted February 07, 2023 12:14 pm by C10H12N2
(13)
Without an uplist to NASDAQ this stock will most likely remain in the gutter. People want to see data and uplist ro NASDAQ. They have been royally screwed with the 100 to 1 reverse spilit based on an
...read more
posted February 06, 2023 04:19 pm by waves1
(223)
With one study in progress and another incoming, AGN is has an established plan for this year and could easily see some catalysts here.
rate and reply
posted February 05, 2023 03:43 pm by C10H12N2
(13)
The spread of the avian influenza virus on a mink farm in Spain has some scientists on edge. “This is an infection that has epidemic and pandemic potential,” Dr. Isaac Bogoch, a Toronto-based
...read more
posted February 03, 2023 02:46 pm by StockDoctor101
(39)
Lot of upcoming milestones which could get AGN moving. Look out for data from phase 1 of the DMT study in Q2 of this year along with the beginning of a phase 2b IPF study for chronic cough also set
...read more
posted February 02, 2023 02:28 pm by SkywalkerofLuke
(245)
New interview with AGN.c AGNPF CEO (up 5% today). Gives updates on the previously announced 180 patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough that will begin in Q3. The
...read more
posted February 01, 2023 06:36 pm by C10H12N2
(13)
The CEO claims all your woes are because Penny Stock Investors @ CSE & OTC are stupid people. The CEO has stated the same thing in the recent past then retracted. Says he was misunderstood. Yet
...read more
posted February 01, 2023 03:12 pm by StockDoctor101
(39)
AGN looking to wrap up the DMT phase 1 study some time in June or July. Some solid data from the study in Q2 or Q3 this year could be huge for AGN. Will be on the lookout for more updates here. A
...read more
posted January 31, 2023 05:08 pm by waves1
(223)
Insightful interview - there is significant potential here as the phase 2a study showed a significant improvement in patients Ifenprodil is a novel first-in-class potential treatment for chronic
...read more
posted January 30, 2023 06:44 pm by StockHawk1
(330)
Algernon Pharmaceuticals (AGN.c AGNPF) CEO, Christopher Moreau, on Radius Research giving an update on the company's Ifendprodil drug program which aim to test if the drug can help with chronic
...read more
posted January 30, 2023 05:59 pm by C10H12N2
(13)
https://electratect.com/about-om
rate and reply
posted January 30, 2023 12:20 pm by bmreed
(78)
News Update: Algernon Pharmaceuticals $AGN w CEO Christopher Moreau - Pitch, Deep Dive and Q&A - https://youtu.be/zpvV0-fELgc CEO Christopher Moreau provides an update on its
...read more
posted January 27, 2023 05:45 pm by StockHawk1
(330)
Algernon Pharmaceuticals (AGN.c AGNPF) CEO on the company's Phase 1 DMT Clinical Stroke Study, why the company decided to create a subsidiary for its DMT research (Algernon Nuro) and plans to
...read more
posted January 27, 2023 03:37 pm by C10H12N2
(13)
Take a look at the performance of Xortx Therapeutics (XRTX) today with its recent move towards a Phase III clinical trial. They're now at 52 week low with no bottom. The relevance is Xortx's
...read more
posted January 27, 2023 02:12 pm by stockpatrol
(272)
Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals, has begun a Phase 1 clinical stroke study of DMT in the Netherlands, using a single-escalating dose design to determine a safe, non
...read more
posted January 26, 2023 09:10 am by C10H12N2
(13)
My best guess is over the course of Moreau's management style the big winner in the entire equation is someone whom management (CEO, CSO, CFO) has had a blatant conflict of interest relationship
...read more
posted January 26, 2023 08:09 am by C10H12N2
(13)
@ Radius Research the Interviewer hits the correct number of 150% Dilution with a capital raise of 10M USD. Then turns right around and says a capital raise of 10M USD through Algernon Neuro only
...read more
posted January 25, 2023 03:58 pm by SkywalkerofLuke
(245)
Thanks for the share, great to hear the positive feedback from psychedelic funds on the study.
rate and reply
posted January 25, 2023 03:08 pm by waves1
(223)
AGN CEO Chris Moreau on Radius Research discussing the latest
...read more
posted January 24, 2023 05:00 pm by waves1
(223)
There is significant potential here as AGN is taking a new approach to stroke treatment that greatly differs from the previous stroke drug treatments that failed. By focusing on promoting
...read more